Active Surveillance

Dr. Barken discusses the article: Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: Finding a new group eligible for active surveillance.  Urol Int. Feb 5 , 2013.

This entry was posted in Active Surveillance, Treatments for Prostate Cancer and tagged , . Bookmark the permalink.